查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1829123

1 型糖尿病治療市場（按胰島素類型、給藥方式、患者年齡層、分銷管道和最終用戶分類）—2025-2032 年全球預測

Type 1 Diabetes Drug Market by Insulin Type, Delivery Mode, Patient Age Group, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，1 型糖尿病藥物市場將成長至 390.7 億美元，複合年成長率為 9.32%。

主要市場統計數據
基準年2024年 191.4億美元
預計2025年 209.3億美元
預測年份：2032年 390.7億美元
複合年成長率（%） 9.32%

策略介紹框架，闡述臨床創新、政策轉變和商業動態之間的相互作用，重新定義 1 型糖尿病照護和相關人員的優先事項

1型糖尿病仍然是一種複雜的慢性疾病，需要精準的臨床管理、持續的技術創新以及支付者和醫療機構的協調參與。過去十年，胰島素製劑和給藥技術的臨床進展與監管部門對數位醫療解決方案和可負擔性的關注相輔相成。因此，產業、臨床和政策相關人員正在重新評估各自的優先事項，以更好地將治療價值與以病人為中心的醫療服務結合。

本執行摘要概述了推動第1型糖尿病治療的關鍵力量，並強調了臨床創新如何與供應鏈動態和商業策略交織在一起。此外，它還強調了當代政策辯論和擬議關稅調整的影響，這些因素可能對產品流動和成本結構產生重大影響。本摘要旨在透過闡明臨床需求、技術能力和經濟約束之間的交匯點，為策略規劃提供綜合基礎。

讀者將找到一個簡潔的當前環境框架，一個清晰且基於證據的變革動態解釋，以及一條協調專案和商業性應對措施的實用路徑。本書的引言也為後續更深入的討論奠定了基礎，涵蓋細分市場、區域模式、公司定位以及可操作的建議，旨在幫助領導者將洞察轉化為優先行動。

臨床進展、醫療服務創新和政策壓力如何重塑 1 型糖尿病治療的商業策略和患者期望

1型糖尿病治療領域正在經歷變革性變革，這得益於製劑科學、給藥系統、數位整合以及強調可及性和可負擔性的政策的同步進步。臨床上，胰島素類似物製劑和輔助性治療的逐步改進，加上閉合迴路胰島素給藥和感測器技術的創新，正在提升血糖穩定性和生活品質的前景。這些技術變革正在改變臨床醫生的處方方式、患者的日常用藥管理方式以及支付方評估價值提案的方式。

同時，商業模式也在不斷演變。製造商正在透過胰島素類型和給藥方式來豐富產品系列，同時投資於患者支援服務和數位化依從性工具，以使其產品更具差異化。從注射筆和幫浦到貼片裝置和預填充注射器，給藥方式的創新正在將醫療服務中心轉向更自主的家庭管理，並為競爭差異化創造新的管道。監管機構和報銷機構越來越關注現實世界的療效和成本效益，推動更嚴格的證據要求，並更加重視衛生經濟學和療效研究。

此外，生物相似藥、策略夥伴關係以及加速互補技術取得的定向收購正在重塑競爭格局。這些因素，加上公眾對定價和分銷實踐的審查力度不斷加大，正在建立一個更加整合的生態系統，在這個生態系統中，臨床療效、患者體驗和可負擔性必須相互協調。能夠協調產品開發、服務模式和政策參與的相關人員將更有能力獲取價值並改善病患治療效果。

評估 2025 年美國關稅變化對第 1 型糖尿病藥物供應鏈、定價動態和上市策略的累積影響

2025年美國新關稅的實施，將引發整個1型糖尿病價值鏈的供應鏈設計、籌資策略和成本管理的重要考量。進口零件、成品和包裝材料的關稅調整可能會增加胰島素製劑和給藥系統的到岸成本，迫使製造商和經銷商重新考慮其採購佈局和庫存策略。為此，許多公司將評估近岸外包、雙重採購或增加本地生產，以緩解進口關稅和相關的物流波動。

這些政策轉變也將影響定價動態以及與付款人和綜合交付網路的合約關係。日益成長的成本壓力可能會加速有關製造商返利、處方藥目錄配置以及將醫療設備報銷與已證實的臨床結果掛鉤的捆綁式醫療安排的談判。同時，單位成本的上升（尤其是在共同支付持續的情況下）可能會對患者的負擔能力造成壓力，從而加劇患者援助計劃和替代資金籌措模式的緊迫性。

從營運角度來看，關稅可能會增加與庫存積壓和通路庫存相關的財務風險，從而擾亂既定的新產品發布和生命週期管理時間表。因此，產品團隊需要整合產品發布計劃和採購契約，並將關稅的影響納入考慮。重要的是，關稅環境將提升面向製造設計決策的策略價值，從而減少對關稅投入的依賴，並提升數位化工具的策略價值，從而最佳化分銷效率。總而言之，2025年的關稅環境將成為整個1型糖尿病生態系統中更具彈性、更具成本意識和更具地域導向的供應鏈策略的催化劑。

關鍵細分洞察揭示了胰島素類型、給藥方式、患者人口統計、分銷選擇和最終用戶偏好如何獨特地塑造臨床和商業策略

細分分析揭示了差異化的臨床和商業性途徑，值得我們給予單獨的策略關注。根據胰島素類型，中效製劑、長效類似物、速效製劑和短效胰島素製劑的產品開發和臨床定位有所不同，每類製劑針對不同的治療適應症和依從性。胰島素類型的選擇也會與給藥偏好和臨床方案相互影響，進而影響處方協商和處方模式。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 每週一次的 GLP-1 受體促效劑的出現改善了第 1 型糖尿病患者的血糖控制
  • 數位健康整合推動封閉回路型胰島素輸送系統的快速應用
  • 以合併使用升糖素減少低血糖發作為目標的雙激素幫浦治療進展
  • 開發口服胰島素類似物產品線，以提高患者依從性並減少注射負擔
  • 免疫調節療法在第一型糖尿病早期診斷中維持BETA細胞功能的作用
  • 擴展連續酮監測技術以預防門診糖尿病酮酸症

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 1 型糖尿病治療市場（按胰島素類型）

  • 中效型
  • 長效
  • 快速起效
  • 短效

9. 1 型糖尿病藥物市場（依給藥方式）

  • 筆
    • 免洗筆
    • 可重複使用的筆
  • 泵浦
    • 胰島素幫浦
    • 貼片幫浦
  • 注射器
    • 預填充式注射器
    • 管瓶和注射器

第 10 章：1 型糖尿病治療市場（依患者年齡層）

  • 成人
  • 老年人
  • 孩子們

第 11 章 1 型糖尿病藥物市場（依分銷管道）

  • 離線
  • 線上

第 12 章：1 型糖尿病藥物市場（按最終用戶分類）

  • 診所
    • 基層醫療診所
    • 專科診所
  • 居家護理
    • 看護者管理
    • 自我管理
  • 醫院
    • 私立醫院
    • 公立醫院

第 13 章 1 型糖尿病藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章 1 型糖尿病藥物市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章 1 型糖尿病藥物市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Novo Nordisk A/S
    • Sanofi SA
    • Eli Lilly and Company
    • Biocon Limited
    • Viatris Inc.
    • Wockhardt Limited
    • MannKind Corporation
    • Dr. Reddy's Laboratories Limited
    • Glenmark Pharmaceuticals Limited
    • Lupin Limited
Product Code: MRR-43676CF429EB

The Type 1 Diabetes Drug Market is projected to grow by USD 39.07 billion at a CAGR of 9.32% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 19.14 billion
Estimated Year [2025] USD 20.93 billion
Forecast Year [2032] USD 39.07 billion
CAGR (%) 9.32%

A strategic introduction framing the interplay of clinical innovation, policy shifts, and commercial dynamics that are redefining Type 1 diabetes care and stakeholder priorities

Type 1 diabetes remains a complex chronic condition that requires precise clinical management, continuous technological innovation, and coordinated payer and provider engagement. Over the past decade, clinical advances in insulin formulation and delivery technologies have been complemented by digital health solutions and regulatory attention on affordability, which together have redefined expectations for patient outcomes and system-level efficiency. As a result, stakeholders across industry, clinical practice, and policy are reassessing priorities to better align therapeutic value with patient-centered care.

This executive summary synthesizes the dominant forces driving the Type 1 therapeutic landscape, highlighting how clinical innovations intersect with supply chain dynamics and commercial strategies. It also surfaces the implications of contemporary policy debates and proposed tariff shifts that may materially affect product flows and cost structures. The aim is to provide an integrated foundation for strategic planning by clarifying where clinical need, technological capability, and economic constraints converge.

Readers will find a concise framing of the current environment, an evidence-based articulation of transformative dynamics, and pragmatic pathways for aligning programmatic and commercial responses. In doing so, this introduction sets the stage for deeper examination of segmentation, regional patterns, company positioning, and actionable recommendations that follow, ensuring that leaders can translate insight into prioritized action.

How converging clinical advances, delivery innovation, and policy pressure are reshaping commercial strategies and patient expectations across Type 1 diabetes care

The therapeutic landscape for Type 1 diabetes is experiencing transformative shifts driven by simultaneous advances in formulation science, delivery systems, digital integration, and policy focus on access and affordability. On the clinical front, incremental improvements in insulin analogs and adjunctive therapies are being matched by innovations in closed-loop insulin delivery and sensor technologies, which together are raising expectations for glycemic stability and quality-of-life improvements. These technological inflections are changing how clinicians prescribe, how patients manage daily regimens, and how payers evaluate value propositions.

Concurrently, commercial models are evolving: manufacturers are diversifying product portfolios across insulin types and delivery formats while investing in patient support services and digital adherence tools to differentiate offerings. Delivery mode innovation - from pens and pumps to patch devices and prefilled injectables - is shifting the locus of care toward more autonomous, home-based management and creating new channels for competitive differentiation. Regulatory and reimbursement agencies are increasingly focused on real-world outcomes and cost-effectiveness, prompting tighter evidence requirements and greater emphasis on health economics and outcomes research.

Moreover, the competitive field is being reshaped by biosimilars, strategic partnerships, and targeted acquisitions that accelerate access to complementary technologies. These factors, in combination with heightened public scrutiny of pricing and distribution practices, are producing a more integrated ecosystem in which clinical efficacy, patient experience, and affordability must be addressed in concert. Stakeholders that align product development, service models, and policy engagement will be better positioned to capture value and deliver improved patient outcomes.

Assessing the cumulative effects of the United States tariff changes in 2025 on supply chains, pricing dynamics, and commercial launch strategies within Type 1 diabetes therapeutics

The introduction of new tariff measures in the United States in 2025 creates material considerations for supply chain design, procurement strategies, and cost management across the Type 1 diabetes value chain. Tariff adjustments on imported components, finished devices, or packaging materials can increase landed costs for insulin products and delivery systems, prompting manufacturers and distributors to reconsider sourcing footprints and inventory strategies. In response, many organizations will evaluate nearshoring, dual-sourcing, or increased local manufacturing to mitigate exposure to import duties and related logistical volatility.

These policy shifts also influence pricing dynamics and contracting relationships with payers and integrated delivery networks. Heightened cost pressure can accelerate negotiation around manufacturer rebates, formulary placement, and bundled care arrangements that link device reimbursement to demonstrated clinical outcomes. At the same time, higher unit costs may strain affordability for patients, especially where out-of-pocket exposure persists, thereby intensifying the urgency for patient-assistance programs and alternative financing models.

Operationally, tariffs can disrupt established timelines for new product launches and lifecycle management by increasing the financial risk associated with inventory accumulation and channel stocking. Consequently, product teams will need to integrate tariff sensitivity into commercial launch plans and procurement contracts. Importantly, the tariff environment amplifies the strategic value of design-for-manufacture decisions that reduce dependence on tariffed inputs and of digital tools that optimize distribution efficiency. Taken together, the 2025 tariff landscape is a catalyst for more resilient, cost-aware, and locally orientated supply chain strategies across the Type 1 diabetes ecosystem.

Key segmentation insights revealing how insulin types, delivery modalities, patient age cohorts, distribution choices, and end-user settings uniquely shape clinical and commercial strategies

Segmentation analysis reveals differentiated clinical and commercial pathways that merit discrete strategic attention. Based on insulin type, product development and clinical positioning diverge across intermediate-acting formulations, long-acting analogs, rapid-acting preparations, and short-acting insulins, with each class serving distinct therapeutic indications and adherence profiles. The selection of insulin type also interacts with delivery preferences and clinical protocols, influencing formulary negotiations and prescribing patterns.

Based on delivery mode, the ecosystem spans pens, pumps, and syringes, with significant nuance embedded in device subtypes. Pen options include disposable and reusable pens that offer different trade-offs in cost, convenience, and environmental profile. Pump technologies bifurcate into traditional insulin pumps and emerging patch pump designs, each creating distinct opportunities for integration with continuous glucose monitoring and algorithmic dosing. Syringe-based delivery remains relevant through both prefilled syringes and vial-and-syringe offerings, serving specific patient segments and clinical situations where simplicity or cost-containment is prioritized.

Based on patient age group, therapeutic needs and service delivery models differ across adult, geriatric, and pediatric populations, with pediatric care emphasizing caregiver education and tailored dosing, geriatric care prioritizing comorbidity management and simplified regimens, and adult care spanning a broad spectrum of lifestyle and occupational considerations. Based on distribution channel, offline and online pathways are both influential; brick-and-mortar pharmacies and clinics maintain importance for immediacy and clinical oversight, while digital pharmacies and telehealth platforms are expanding access and facilitating home delivery and remote monitoring. Based on end user, clinics, home care, and hospitals represent distinct demand centers. Clinics are further segmented into primary care and specialty clinics, each with their own prescribing behavior and procurement models. Home care differentiates between caregiver administration and self administration, which shapes education and support needs. Hospitals divide into private and public institutions with divergent procurement cycles, reimbursement pressures, and acute care priorities. Integrating these segmentation dimensions enables targeted product design, differentiated service offerings, and finely tuned commercialization strategies.

Regional dynamics and differentiated entry strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific that influence access, adoption, and commercialization

Regional dynamics create differentiated opportunity windows and operational challenges for product developers and suppliers. In the Americas, commercial dynamics are characterized by a mix of advanced delivery adoption, intense payer negotiation, and ongoing public policy attention to affordability and patient assistance, which together influence pricing strategies, reimbursement pathways, and patient access programs. The Americas also show concentrated pockets of digital health adoption that accelerate the uptake of integrated insulin delivery and monitoring systems.

In Europe, Middle East & Africa, heterogeneous regulatory environments and variable healthcare financing structures create a mosaic of entry requirements and reimbursement timelines. This region often requires tailored market access strategies that account for national formulary processes, tendering behaviors, and local manufacturing incentives. Emerging markets within the region present growth potential but demand flexible pricing and distribution approaches that match local healthcare capacities and procurement norms.

In Asia-Pacific, demand is driven by a combination of rapid technology adoption in some high-income markets and broad population-level needs in larger middle-income countries. Local manufacturing capabilities, strategic partnerships, and policy initiatives to improve chronic disease management shape product design and commercialization. Across all regions, differences in insulin type preference, device adoption rates, distribution channel maturity, and payer architecture necessitate region-specific pathways to market entry, clinical evidence generation, and patient support programming.

How integrated product, device, and service strategies are reshaping competitive positioning and driving new partnerships and differentiators across the Type 1 diabetes field

The competitive landscape in Type 1 diabetes therapeutics is increasingly defined by integrated offers that combine pharmacology, delivery technology, and digital services. Leading pharmaceutical innovators continue to invest in next-generation insulin analogs and device platforms while emerging players and device specialists introduce disruptive form factors such as patch pumps and algorithm-enabled closed-loop systems. Strategic collaborations between drug developers, medtech firms, and digital health vendors are accelerating time-to-market for integrated solutions and creating bundled offerings that are attractive to health systems seeking measurable improvements in outcomes.

Concurrently, competition is intensifying around service ecosystems: patient support programs, remote monitoring, and adherence-enhancing solutions have become standard differentiators. Companies that can demonstrate improvements in real-world glycemic control, reductions in acute event utilization, and clear pathways to lowering total cost of care are securing more favorable payer engagements and formulary access. Supply chain agility and manufacturing footprint also matter more as tariff and trade considerations prompt buyers to prioritize suppliers with resilient, localized capabilities.

New entrants and specialized device makers exert pressure on incumbents by focusing on niche patient needs, simplified user experiences, and lower-cost manufacturing models. In response, established firms are leveraging scale, regulatory experience, and broad clinical datasets to defend positions while selectively partnering to fill capability gaps. The net effect is a landscape in which clinical differentiation, product-service integration, and operational resilience determine competitive advantage.

Actionable strategic priorities for industry leaders to align clinical innovation, supply resilience, and patient access while maximizing commercial and therapeutic impact

Industry leaders should prioritize a coordinated set of actions to navigate clinical innovation, policy dynamics, and supply chain shifts. First, integrate device and digital service development with core pharmaceutical programs to deliver bundled value propositions that address adherence, monitoring, and outcomes measurement. This alignment should include clear evidence generation plans that emphasize real-world outcomes and health economic benefit, enabling stronger payer conversations and differentiated contracting.

Second, reassess sourcing and manufacturing strategies to reduce exposure to tariff volatility and logistical disruption. Where feasible, pursue localized manufacturing or strategic partnerships that shorten supply chains and improve responsiveness. Concurrently, embed tariff sensitivity into commercial forecasting and launch planning so procurement and pricing decisions reflect potential cost pressures.

Third, tailor commercialization pathways by leveraging segmentation insights: align product variants and service offers to the clinical needs of adult, geriatric, and pediatric populations; optimize delivery-mode portfolios across pens, pumps, and syringe formats; and adapt distribution strategies to regional channel maturity. Fourth, enhance patient affordability and access through creative contracting, patient-assistance programs, and digital-enabled adherence initiatives that reduce total cost of care and improve uptake.

Finally, invest in collaborative ecosystems that bridge pharmaceutics, medtech, and digital health expertise. Form strategic alliances with device innovators and data analytics firms to accelerate integrated solutions and scale evidence capture. By combining these strategic moves, organizations can strengthen market positioning while advancing patient-centered outcomes.

Transparent multi-method research methodology combining primary interviews, scenario analysis, and cross-regional comparison to ensure robust and reproducible insights

This research synthesizes primary and secondary sources using a multi-method approach designed to ensure thematic depth and methodological transparency. Primary inputs include structured interviews with clinical specialists, procurement leaders, and industry executives, supplemented by subject-matter workshops that validated emergent hypotheses and triangulated qualitative insights. Secondary inputs encompass peer-reviewed clinical literature, regulatory guidance documents, and public policy statements that inform analysis of clinical practice trends and reimbursement dynamics.

Analytical methods combined thematic coding of qualitative interviews with comparative evaluation of device and therapy feature sets. Scenario analysis was employed to assess the operational implications of tariff changes and supply chain disruptions, while value-mapping exercises linked clinical endpoints to potential payer considerations. Cross-regional comparison used consistent frameworks to surface differences in regulatory, reimbursement, and distribution environments.

Quality assurance involved iterative review cycles with external clinical advisors and industry experts to test assumptions and refine conclusions. Wherever possible, claims are anchored to verifiable sources and subject-matter validation. Limitations and assumptions are documented in the full report, along with appendices that detail interview methodologies, sampling frames, and analytical templates to support reproducibility and client scrutiny.

Concluding synthesis that integrates clinical, commercial, and policy imperatives to guide strategic choices and catalyze targeted action in Type 1 diabetes care

In conclusion, the Type 1 diabetes landscape is undergoing a sustained reorientation driven by advances in insulin formulations, delivery innovation, digital integration, and heightened policy scrutiny around affordability and access. These forces are compelling stakeholders to design solutions that combine pharmacologic efficacy with user-friendly delivery mechanisms and supportive services that demonstrate measurable real-world outcomes. The increasing complexity of payer expectations and the potential implications of trade policy changes necessitate more integrated planning across R&D, supply chain, and commercial functions.

To succeed in this environment, organizations must adopt holistic strategies that align product differentiation, evidence generation, and channel execution. This includes segment-specific product and service design, resilient sourcing strategies, and partnerships that close capability gaps quickly. By doing so, manufacturers and providers can better meet clinician and patient needs while navigating economic and regulatory uncertainty.

Ultimately, the organizations that most effectively blend clinical innovation with operational resilience and patient-centric commercial models will be best positioned to deliver improved outcomes and sustainable value for people living with Type 1 diabetes. The insights in this executive summary are intended to inform those strategic choices and to catalyze targeted action.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of once-weekly GLP-1 receptor agonists showing improved glycemic control in type 1 patients
  • 5.2. Rapid adoption of hybrid closed-loop insulin delivery systems driven by digital health integration
  • 5.3. Advances in dual-hormone pump therapy targeting glucagon co-administration to reduce hypoglycemic events
  • 5.4. Pipeline development of oral insulin analogs aiming to improve patient adherence and reduce injection burden
  • 5.5. Role of immunomodulatory therapies in preserving beta cell function during early type 1 diabetes diagnosis
  • 5.6. Expansion of continuous ketone monitoring technologies to prevent diabetic ketoacidosis in outpatient settings

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Type 1 Diabetes Drug Market, by Insulin Type

  • 8.1. Intermediate-Acting
  • 8.2. Long-Acting
  • 8.3. Rapid-Acting
  • 8.4. Short-Acting

9. Type 1 Diabetes Drug Market, by Delivery Mode

  • 9.1. Pen
    • 9.1.1. Disposable Pen
    • 9.1.2. Reusable Pen
  • 9.2. Pump
    • 9.2.1. Insulin Pump
    • 9.2.2. Patch Pump
  • 9.3. Syringe
    • 9.3.1. Prefilled Syringe
    • 9.3.2. Vial And Syringe

10. Type 1 Diabetes Drug Market, by Patient Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Type 1 Diabetes Drug Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Type 1 Diabetes Drug Market, by End User

  • 12.1. Clinics
    • 12.1.1. Primary Care Clinics
    • 12.1.2. Specialty Clinics
  • 12.2. Home Care
    • 12.2.1. Caregiver Administration
    • 12.2.2. Self Administration
  • 12.3. Hospitals
    • 12.3.1. Private Hospitals
    • 12.3.2. Public Hospitals

13. Type 1 Diabetes Drug Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Type 1 Diabetes Drug Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Type 1 Diabetes Drug Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novo Nordisk A/S
    • 16.3.2. Sanofi S.A.
    • 16.3.3. Eli Lilly and Company
    • 16.3.4. Biocon Limited
    • 16.3.5. Viatris Inc.
    • 16.3.6. Wockhardt Limited
    • 16.3.7. MannKind Corporation
    • 16.3.8. Dr. Reddy's Laboratories Limited
    • 16.3.9. Glenmark Pharmaceuticals Limited
    • 16.3.10. Lupin Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TYPE 1 DIABETES DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INTERMEDIATE-ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INTERMEDIATE-ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INTERMEDIATE-ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INTERMEDIATE-ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INTERMEDIATE-ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INTERMEDIATE-ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID-ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID-ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID-ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID-ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID-ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID-ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SHORT-ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SHORT-ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SHORT-ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SHORT-ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SHORT-ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SHORT-ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISPOSABLE PEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISPOSABLE PEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISPOSABLE PEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISPOSABLE PEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISPOSABLE PEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISPOSABLE PEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REUSABLE PEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REUSABLE PEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REUSABLE PEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REUSABLE PEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REUSABLE PEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REUSABLE PEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATCH PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATCH PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATCH PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATCH PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATCH PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATCH PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY VIAL AND SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY VIAL AND SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY VIAL AND SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY VIAL AND SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY VIAL AND SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY VIAL AND SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY PEN, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY PUMP, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 325. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 326. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 327. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 328. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 329. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE